Cargando…
Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab
Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759913/ https://www.ncbi.nlm.nih.gov/pubmed/33266022 http://dx.doi.org/10.3390/nu12123699 |
_version_ | 1783627209119891456 |
---|---|
author | Bendix, Mia Dige, Anders Jørgensen, Søren Peter Dahlerup, Jens Frederik Bibby, Bo Martin Deleuran, Bent Agnholt, Jørgen |
author_facet | Bendix, Mia Dige, Anders Jørgensen, Søren Peter Dahlerup, Jens Frederik Bibby, Bo Martin Deleuran, Bent Agnholt, Jørgen |
author_sort | Bendix, Mia |
collection | PubMed |
description | Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34. |
format | Online Article Text |
id | pubmed-7759913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77599132020-12-26 Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab Bendix, Mia Dige, Anders Jørgensen, Søren Peter Dahlerup, Jens Frederik Bibby, Bo Martin Deleuran, Bent Agnholt, Jørgen Nutrients Article Background: Vitamin D treatment may reduce Crohn’s disease (CD) activity by modulating the mucosal immune function. We investigated if high-dose vitamin D +/− infliximab modulated the mucosal cytokine expression in active CD. Methods: Forty CD patients were randomized into: infliximab + vitamin D; infliximab + placebo-vitamin D; placebo-infliximab + vitamin D or placebo-infliximab + placebo-vitamin D. Infliximab (5 mg/kg) and placebo-infliximab were administered at weeks 0, 2 and 6. Oral vitamin D was administered as bolus 200,000 international units (IU) per week 0 followed by 20,000 IU/day for 7 weeks or placebo. Endoscopy with biopsies was performed at weeks 0 and 7 where endoscopic activity was measured and mucosal mRNA cytokine expression was examined. C-reactive protein (CRP), fecal calprotectin and Harvey-Bradshaw Index (HBI) were measured at weeks 0, 2 and 6. Results: High-dose vitamin D treatment alone and combined with infliximab decreased the IL17A, IFNγ and IL10 expression. High-dose vitamin D alone did not significantly decrease the disease activity, CRP or calprotectin. Combined infliximab and vitamin D treatment was not clinically significantly superior to monotherapy with infliximab. Conclusions: High-dose vitamin D as monotherapy and combined with infliximab decreases IL17A, IFNγ and IL-10 expression in mucosa within treatment groups. This did not induce a statistically significant decreased disease activity. EudraCT no.2013-000971-34. MDPI 2020-11-30 /pmc/articles/PMC7759913/ /pubmed/33266022 http://dx.doi.org/10.3390/nu12123699 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bendix, Mia Dige, Anders Jørgensen, Søren Peter Dahlerup, Jens Frederik Bibby, Bo Martin Deleuran, Bent Agnholt, Jørgen Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title | Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title_full | Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title_fullStr | Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title_full_unstemmed | Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title_short | Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin D Alone or Combined with Infliximab |
title_sort | decrease in mucosal il17a, ifnγ and il10 expressions in active crohn’s disease patients treated with high-dose vitamin d alone or combined with infliximab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759913/ https://www.ncbi.nlm.nih.gov/pubmed/33266022 http://dx.doi.org/10.3390/nu12123699 |
work_keys_str_mv | AT bendixmia decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT digeanders decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT jørgensensørenpeter decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT dahlerupjensfrederik decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT bibbybomartin decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT deleuranbent decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab AT agnholtjørgen decreaseinmucosalil17aifngandil10expressionsinactivecrohnsdiseasepatientstreatedwithhighdosevitamindaloneorcombinedwithinfliximab |